Mutagenic mechanisms in normal and neoplastic B cells: from AID-induced diversification to genome-wide patterns

Sepúlveda Yáñez, J.H.

LIST OF PUBLICATIONS AND CONFERENCE PRESENTATIONS

PUBLICATIONS IN THIS THESIS

Sepúlveda-Yáñez, J. H., Alvarez-Saravia, D., Fernández-Goycoolea, J., Aldridge, J., van Bergen, C. A. M., Posthuma, W., Uribe-Paredes, R., Veelken, H., & Navarrete, M. A. (2021). Integration of mutational signature analysis with 3D chromatin data unveils differential AID-related mutagenesis in indolent lymphomas. International Journal of Molecular Sciences, 22(23), 13015.

Sepúlveda-Yáñez, J. H., Alvarez Saravia, D., Pilzecker, B., van Schouwenburg, P. A., van den Burg, M., Veelken, H., Navarrete, M. A., Jacobs, H., & Koning, M. T. (2022). Tandem substitutions in somatic hypermutation. Frontiers in Immunology, 12, 807015.

Quinten, E., **Sepúlveda-Yáñez, J. H.**, Koning, M. T., Eken, J. A., Pfeifer, D., Nteleah, V., de Groen, R. A. L., Saravia, D. A., Knijnenburg, J., Stuivenberg-Bleijswijk, H. E., Pantic, M., Agathangelidis, A., Keppler-Hafkemeyer, A., van Bergen, C. A. M., Uribe-Paredes, R., Stamatopoulos, K., Vermaat, J. S. P., Zirlik, K., Navarrete, M. A., Jumaa, H., & Veelken, H. (2023). Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia. Haematologica, 109(3), 824-834.

Sepúlveda-Yáñez, J. H., Saravia, D. A., Medina, D., Quinten, E., Kloet, S., Jansen, P. M., Posthuma, E. W. M., Kiełbasa, S. M., van Bergen, C. A. M., Navarrete, M. A., & Veelken, H. (2024). Detection of occurrent somatic hypermutation and associated gene expression profile in single. Blood Cancer Discovery. Manuscript under review.

PUBLICATIONS NOT IN THE THIS THESIS

Cabas-Mora, G., Daza, A., Soto-García, N., Garrido, V., Alvarez, D., Navarrete, M., Sarmiento-Varón, L., Yañez, J. H. S., Davari, M. D., Cadet, F., Olivera-Nappa, Á., Uribe-Paredes, R., & Medina-Ortiz, D. (2024). Peptipedia v2.0: A peptide sequence database and user-friendly web platform. A major update (p. 2024.07.11.603053). bioRxiv. https://doi.org/10.1101/2024.07.11.603053
Eken, J. A., Koning, M. T., Kupcova, K., **Sepúlveda Yáñez, J. H.**, de Groen, R. A. L., Quinten, E., Janssen, J., van Bergen, C. A. M., Vermaat, J. S. P., Cleven, A., Navarrete, M. A., Ylstra, B., de Jong, D., Havranek, O., Jumaa, H., & Veelken, H. (2024). Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. Journal of Experimental Medicine, 221(5), e20230941. https://doi.org/10.1084/jem.20230941

Goles, M., Daza, A., Cabas-Mora, G., Sarmiento-Varón, L., **Sepúlveda-Yañez, J.**, Anvari-Kazemabad, H., Davari, M. D., Uribe-Paredes, R., Olivera-Nappa, Á., Navarrete, M. A., & Medina-Ortiz, D. (2024). Peptide-based drug discovery through artificial intelligence: Towards an autonomous design of therapeutic peptides. Briefings in Bioinformatics, 25(4), bbae275. https://doi.org/10.1093/bib/bbae275

Morande, P. E., Yan, X.-J., **Sepulveda, J.**, Seija, N., Marquez, M. E., Sotelo, N., Abreu, C.,

Crispo, M., Fernández-Graña, G., Rego, N., Bois, T., Methot, S. P., Palacios, F., Remedi, V., Rai, K. R., Buschiazzo, A., Di Noia, J. M., Navarrete, M. A., Chiorazzi, N., & Oppezzo, P. (2021). AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms. Blood, 138(3), 246–258. https://doi.org/10.1182/blood.2020008654

Shafighi, S. D., Kiełbasa, S. M., **Sepúlveda-Yáñez, J.**, Monajemi, R., Cats, D., Mei, H., Menafra, R., Kloet, S., Veelken, H., van Bergen, C. A. M., & Szczurek, E. (2021). CACTUS: Integrating clonal architecture with genomic clustering and transcriptome profiling of single tumor cells. Genome Medicine, 13(1), 45. https://doi.org/10.1186/s13073-021-00842-w

van Bergen, C. A. M., Kloet, S. L., Quinten, E., **Sepúlveda Yáñez, J. H.**, Menafra, R., Griffioen, M., Jansen, P. M., Koning, M. T., Knijnenburg, J., Navarrete, M. A., Kiełbasa, S. M., & Veelken, H. (2023). Acquisition of a glycosylated B-cell receptor drives follicular lymphoma toward a dark zone phenotype. Blood Advances, 7(19), 5812–5816. https://doi.org/10.1182/bloodadvances.2023010725

CONFERENCE PRESENTATIONS

59th American Society of hematology (ASH) Annual Meeting and Exposition, Atlanta, United States (2017) (poster presentation) Sepulveda-Yanez,J.H., van Bergen, C.A.M., Alvarez,D., Kielbasa S.M., Mei H., Veelken, J.H., Navarrete, M.A.

The Mutation Landscape of Follicular Lymphoma and Chronic Lymphocytic Leukemia Reveals a Distinctive Frequency and Composition of Aid-Related Mutation Signatures

60th American Society of hematology (ASH) Annual Meeting and Exposition, San Diego, United States (2018) (poster presentation) Sepulveda-Yanez,J.H., Alvarez,D., Fernandez-Goycoolea, J., van Bergen, C.A.M., Veelken, J.H., Navarrete, M.A.

Differential Genome-Wide Mutational Patterns in Indolent B-Cell Lymphomas

63rd American Society of hematology (ASH) Annual Meeting and Exposition, Atlanta, United States (2021) (poster presentation) Sepulveda-Yanez,J.H., Alvarez,D., Quinten, E., Menafra, R., Kloet, S.L., Monajemi, R., Kielbasa S.M., Navarrete, M.A., van Bergen, C.A.M., Veelken, J.H.

”Snapshotting” Somatic Hypermutation in Single Follicular Lymphoma Cells

63rd American Society of hematology (ASH) Annual Meeting and Exposition, Atlanta, United States (2021) (poster presentation, co-author) Koning, M.T, Sepulveda-Yanez,J.H., Alvarez,D., Pilzecker, B., van Schouwenburg, P., van den Burg, M., Navarrete, M.A., Jacobs, H., Veelken, J.H.

Tandem Substitutions in Somatic Hypermutation

64th American Society of hematology (ASH) Annual Meeting and Exposition, New Orleans, United States (2022) (poster presentation, co-author) Gonzalez-Puelma, J., Sepulveda-Yanez,J.H., Torres-Almonacid, Alvarez,D., Marquez, M.E., Alvarez-Ojeda, H., Cardemil, D., Urive-Paredes, R., Oppezo, P., Navarrete, M.A.

Unbiased NGS Approach for IGHV Mutational Status, Clonal Space and Immune Repertoire Assessment in Chronic Lymphocytic Leukemia

64th American Society of hematology (ASH) Annual Meeting and Exposition, New Orleans, United States (2022) (poster presentation, co-author) Eken, J.A, Koning, M.T, Sepulveda-Yanez,J.H., van Bergen, C.A.M, Quinten, E., Kupcova, K., Havranek, O., De groen, R.A.L, Vermaat, J.S.P, de Jong, D., Kluin, P., Cleven, A., Jumaa., H, Veelken, J.H.

Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

64th American Society of hematology (ASH) Annual Meeting and Exposition, New Orleans, United States (2021) (poster presentation, co-author) Sepulveda-Yanez,J.H., Quinten, E., Koning, M.T, Eken, J.A, Pfeifer, D., De groen, R.A.L, Alvarez-Saravia, D., Agathangelidis, A.,van Bergen, C.A.M, Stamatopoulos, S., Vermaat, J.S.P, Zirlik, K., Navarrete, M.A., Jumaa., H, Veelken, J.H.

Autonomous BCR Signaling and Genetic Aberrations in CLL-Phenotype Monoclonal B Lymphocytosis in Siblings of CLL Patients

CURRICULUM VITAE

Julieta Haydeé Sepúlveda Yáñez was born on October 26, 1987, in Punta Arenas, Chile. In 2005, she completed her high school education at Liceo Juan Bautista Contardi. She earned her bachelor's degree in Medical Technology (2006-2010), specializing in morphophysiopathology and cytodiagnostics at the University of Concepcion, graduating cum laude and as the top of her class. In 2011, she started her master's degree in Biochemistry and Bioinformatics at the University of Concepcion, having received a national scholarship, and graduated cum laude. In 2014, she was appointed as a lecturer at the Universidad de Magallanes. In December 2016, after receiving a national doctoral scholarship, she began her PhD in the Department of Hematology at Leiden University Medical Center. Currently, she is an associate professor in the Faculty of Health Sciences at Universidad de Magallanes.

ACKNOWLEDGEMENT

I have been thinking for a long time about this section of my thesis, maybe for years. And I always come back to the same thought: my first thanks are for my family. I have been so blessed to have the family that I have. My dad, mom, and brother have always believed in me. They made me believe that anything was possible and the sky is the limit. They have always been by my side. I realize how extraordinary is my family, and I feel so fortunate.

This path has been full of people who believed in me and gave me opportunities to move forward. I would like to thank my supervisors. Hendrik gave me the freedom to investigate my own ideas and follow my own process. He provided me with this tools that I think will be priceless for my future career. I also want to thank Marcelo, in Hendrik's words, "he turns everything to gold," and I have seen him do that so many times. Additionally, I want to thank to Kees, he was there in the everyday discussion and he is an "excellent" colleague. I want to add here my gratitude to my lab mates Marvyn, Janneke and Edwin. A special thanks to Diego. I think without his support, I would still be working on my thesis. He has been an essential part of this work. Also my appreciation to all the cATG members who were part of this journey.

When I moved to the Netherlands, I was so afraid but I found an amazing community. I learned so much and felt at home living there. It was a life-changing experience. I am grateful to have chosen Leiden University Medical Center. My thanks to the entire Department of Hematology, both past and present. My deep thanks to Dyantha, Georgia, Miranda, Laura, Lois, Nadine and Tassilo, and a heartfelt thanks to Aicha for all her support. They made my stay amazing, and we shared so many memories and invaluable experiences on this path. Of course, I would also like to thank the Latin American community in the Netherlands. Special gratitude goes to Javiera for her friendship throughout this process.

This has been a long journey. None of this was fortuitous. It was completely deliberate. I dreamed of doing a PhD when I was 19 years old. I remember the exact moment: it was in a biochemistry class during my bachelor's degree in medical technology. A professor explained how the research world works, and at that moment, I knew I wanted to be a researcher. I was motivated by the naive idea that in this way, I could positively impact more lives than in the clinic. This was my driver, and I finished it. This is why I want to thank myself, and I think someone else used the perfect words for this:

"Last but not least, I wanna thank me, I wanna thank me for believing in me, I wanna thank me for doing all this hard work, I wanna thank me for having no days off, I wanna thank me for never quitting, I wanna thank me for always being a giver, and trying to give more than I receive, I wanna thank me for trying to do more right than wrong, I wanna thank me for just being me at all times" - Snoop Dogg

Bibliography

1. Hozumi, N. & Tonegawa, S. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. ***Proc Natl Acad Sci U S A* 73,** 3628–3632 (Oct. 1976).
2. Gellert, M. V(D)J Recombination: RAG Proteins, Repair Factors, and Regulation. ***Annu. Rev. Biochem.* 71.** Publisher: Annual Reviews, 101–132. doi:10.1146/annurev.biochem.71.090501.150203 (June 2002).
3. Schatz, D. G. & Spanopoulou, E. en. in ***Molecular Analysis of B Lymphocyte Development and Activation*** (eds Singh, H. & Grosschedl, R.) Series Title: Current Topics in Microbiology and Immunology, 49–85 (Springer-Verlag, Berlin/Heidelberg, 2005). doi:10.1007/3-540-26363-2_4.
4. Victora, G. D. & Nussenzweig, M. C. Germinal Centers. ***Annual Review of Immunology* 30.** _eprint: https://doi.org/10.1146/annurev-immunol-020711-075032, 429–457. doi:10.1146/annurev-immunol-020711-075032 (2012).
5. Muramatsu, M., Kinoshita, K., ***et al.*** Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. eng. ***Cell* 102.** PMID: 11007474, 553–563. doi:10.1016/s0092-8674(00)00078-7 (Sept. 1, 2000).
6. Begum, N. A., Nagaoka, H., Kobayashi, M. & Honjo, T. en. in ***Molecular Biology of B Cells*** DOI: 10.1016/B978-0-12-397933-9.00018-7, 305–344 (Elsevier, 2015).
7. Muramatsu, M., Kinoshita, K., ***et al.*** Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. eng. ***Cell* 102,** 553–563. doi:10.1016/s0092-8674(00)00078-7 (Sept. 2000).
8. Revy, P., Muto, T., ***et al.*** Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). eng. ***Cell* 102,** 565–575. doi:10.1016/s0092-8674(00)00079-9 (Sept. 2000).
9. Sepúlveda-Yáñez, J. H., Alvarez Saravia, D., ***et al.*** Tandem Substitutions in Somatic Hypermutation. ***Frontiers in Immunology* 12** (2022).
10. Sharbeen, G., Yee, C. W. Y., Smith, A. L. & Jolly, C. J. Ectopic restriction of DNA repair reveals that UNG2 excises AID-induced uracils predominantly or exclusively during G1 phase. eng. ***The Journal of Experimental Medicine* 209,** 965–974. doi:10.1084/jem.20112379 (May 2012).
11. Wang, S., Chahwan, R., Wei, L. & Scharff, M. D. en. in ***Encyclopedia of Immunobiology*** 126–133 (Elsevier, 2016). doi:10.1016/B978-0-12-374279-7.05015-3.
12. Chaudhuri, J., Tian, M., ***et al.*** Transcription-targeted DNA deamination by the AID antibody diversification enzyme. en. ***Nature* 422.** Number: 6933 Publisher: Nature Publishing Group, 726–730. doi:10.1038/nature01574 (Apr. 2003).
13. Pham, P., Bransteitter, R., Petruska, J. & Goodman, M. F. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. en. ***Nature* 424,** 103–107. doi:10.1038/nature01760 (July 2003).
14. Methot, S. P. & Di Noia, J. M. in ***Advances in Immunology*** (ed Alt, F. W.) 37–87 (Academic Press, Jan. 2017). doi:10.1016/bs.ai.2016.11.002.
15. Di Noia, J. M. & Neuberger, M. S. Molecular Mechanisms of Antibody Somatic Hypermuta-

tion. en. *Annual Review of Biochemistry* **76,** 1–22. doi:10.1146/annurev.biochem.76.061705.090740 (June 2007).

16. Storb, U., Shen, H. M. & Nicolae, D. Somatic hypermutation: Processivity of the cytosine deaminase AID and error-free repair of the resulting uracils. *Cell Cycle* **8.** Publisher: Taylor & Francis _eprint: https://doi.org/10.4161/cc.8.19.9658, 3097–3101. doi:10.4161/cc.8.19.9658 (Oct. 2009).
17. Keim, C., Kazadi, D., Rothschild, G. & Basu, U. Regulation of AID, the B-cell genome mutator. *Genes & Development* **27,** 1–17. doi:10.1101/gad.200014.112 (Jan. 2013).
18. Rogozin, I. B. & Diaz, M. Cutting Edge: DGYW/WRCH Is a Better Predictor of Mutability at G:C Bases in Ig Hypermutation Than the Widely Accepted RGYW/WRCY Motif and Probably Reflects a Two-Step Activation-Induced Cytidine Deaminase-Triggered Process. en. *The Journal of Immunology* **172,** 3382–3384. doi:10.4049/jimmunol.172.6.3382 (Mar. 2004).
19. Rogozin, I. B. & Kolchanov, N. A. Somatic hypermutagenesis in immunoglobulin genes: II. Influence of neighbouring base sequences on mutagenesis. en. *Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression* **1171,** 11–18. doi:10.1016/0167-4781(92)90134-L (Nov. 1992).
20. Dörner, T., Foster, S. J., Farner, N. L. & Lipsky, P. E. Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. eng. *European Journal of Immunology* **28,** 3384–3396. doi:10.1002/(SICI)1521-4141(199810)28:10<3384::AID-IMMU3384>3.0.CO;2-T (Oct. 1998).
21. Foster, S. J., Dörner, T. & Lipsky, P. E. Somatic hypermutation of VkappaJkappa rearrangements: targeting of RGYW motifs on both DNA strands and preferential selection of mutated codons within RGYW motifs. eng. *European Journal of Immunology* **29,** 4011–4021. doi:10.1002/(SICI)1521-4141(199912)29:12<4011::AID-IMMU4011>3.0.CO;2-W (Dec. 1999).
22. Mayorov, V. I., Rogozin, I. B., *et al.* Expression of human AID in yeast induces mutations in context similar to the context of somatic hypermutation at G-C pairs in immunoglobulin genes. *BMC Immunology* **6,** 10. doi:10.1186/1471-2172-6-10 (June 2005).
23. Peled, J. U., Kuang, F. L., *et al.* The Biochemistry of Somatic Hypermutation. *Annual Review of Immunology* **26,** 481–511. doi:10.1146/annurev.immunol.26.021607.090236 (Mar. 2008).
24. Matsuda, T., Bebenek, K., *et al.* Error rate and specificity of human and murine DNA polymerase eta. eng. *Journal of Molecular Biology* **312,** 335–346. doi:10.1006/jmbi.2001.4937 (Sept. 2001).
25. Pavlov, Y. I., Rogozin, I. B., *et al.* Correlation of somatic hypermutation specificity and A-T base pair substitution errors by DNA polymerase eta during copying of a mouse immunoglobulin kappa light chain transgene. eng. *Proceedings of the National Academy of Sciences of the United States of America* **99,** 9954–9959. doi:10.1073/pnas.152126799 (July 2002).
26. Zan, H., Komori, A., *et al.* The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. eng. *Immunity* **14,** 643–653. doi:10.1016/s1074-7613(01)00142-x (May 2001).
27. Faili, A., Aoufouchi, S., *et al.* Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota. en. *Nature* **419.** Number: 6910 Publisher: Nature Publishing Group, 944–947. doi:10.1038/nature01117 (Oct. 2002).
28. Ruiz, J. F., Lucas, D., *et al.* Overexpression of human DNA polymerase mu (Pol mu) in a Burkitt's lymphoma cell line affects the somatic hypermutation rate. eng. *Nucleic Acids Research* **32,** 5861–5873. doi:10.1093/nar/gkh929 (2004).
29. Rogozin, I. B., Lada, A. G., *et al.* Activation induced deaminase mutational signature overlaps with CpG methylation sites in follicular lymphoma and other cancers. *Scientific Reports* **6,** 38133. doi:10.1038/srep38133 (Dec. 2016).
30. Rada, C., Williams, G. T., *et al.* Immunoglobulin Isotype Switching Is Inhibited and Somatic Hypermutation Perturbed in UNG-Deficient Mice. en. *Current Biology* **12,** 1748–1755. doi:10.1016/S0960-9822(02)01215-0 (Oct. 15, 2002).
31. Di Noia, J. M. & Neuberger, M. S. Molecular Mechanisms of Antibody Somatic Hypermutation. en. *Annual Review of Biochemistry* **76,** 1–22. doi:10.1146/annurev.biochem.76.061705.090740 (June 7, 2007).
32. Di Noia, J. M., Rada, C. & Neuberger, M. S. SMUG1 is able to excise uracil from immunoglobulin

genes: insight into mutation versus repair. ***The EMBO Journal* 25.** PMID: 16407970 PMCID: PMC1383525, 585–595. doi:10.1038/sj.emboj.7600939 (Feb. 8, 2006).

33. Kemmerich, K., Dingler, F. A., Rada, C. & Neuberger, M. S. Germline ablation of SMUG1 DNA glycosylase causes loss of 5-hydroxymethyluracil- and UNG-backup uracil-excision activities and increases cancer predisposition of Ung-/-Msh2-/- mice. ***Nucleic Acids Research* 40,** 6016–6025. doi:10.1093/nar/gks259 (July 2012).
34. Au, R. Y., Ng, K. S., Chi, L. M. & Lam, S. L. Effect of an abasic site on strand slippage in DNA primer-templates. ***J Phys Chem B* 116,** 14781–7. doi:10.1021/jp308759k (2012).
35. Yousif, A. S., Stanlie, A., Mondal, S., Honjo, T. & Begum, N. A. Differential regulation of S-region hypermutation and class-switch recombination by noncanonical functions of uracil DNA glycosylase. ***Proceedings of the National Academy of Sciences* 111.** Publisher: Proceedings of the National Academy of Sciences, E1016–E1024. doi:10.1073/pnas.1402391111 (Mar. 2014).
36. Dianova, I. I., Bohr, V. A. & Dianov, G. L. Interaction of human AP endonuclease 1 with flap endonuclease 1 and proliferating cell nuclear antigen involved in long-patch base excision repair. eng. ***Biochemistry* 40,** 12639–12644. doi:10.1021/bi011117i (Oct. 2001).
37. Krokan, H. E. & Bjørås, M. Base Excision Repair. en. ***Cold Spring Harbor Perspectives in Biology* 5,** a012583. doi:10.1101/cshperspect.a012583 (Apr. 2013).
38. Ranalli, T. A., DeMott, M. S. & Bambara, R. A. Mechanism underlying replication protein a stimulation of DNA ligase I. eng. ***The Journal of Biological Chemistry* 277,** 1719–1727. doi:10.1074/jbc.M109053200 (Jan. 2002).
39. Vidal, A. E., Boiteux, S., Hickson, I. D. & Radicella, J. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein–protein interactions. ***The EMBO Journal* 20.** PMID: 11707423 PMCID: PMC125722, 6530–6539. doi:10.1093/emboj/20.22.6530 (Nov. 15, 2001).
40. Pham, P., Bransteitter, R., Petruska, J. & Goodman, M. F. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. en. ***Nature* 424,** 103–107. doi:10.1038/nature01760 (July 2003).
41. Yeap, L.-S., Hwang, J. K., ***et al.*** Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody Genes. ***Cell* 163,** 1124–1137. doi:10.1016/j.cell.2015.10.042 (Nov. 2015).
42. Wiesendanger, M., Kneitz, B., Edelmann, W. & Scharff, M. D. Somatic Hypermutation in Muts Homologue (Msh)3-, Msh6-, and Msh3/Msh6-Deficient Mice Reveals a Role for the Msh2–Msh6 Heterodimer in Modulating the Base Substitution Pattern. ***Journal of Experimental Medicine* 191,** 579–584. doi:10.1084/jem.191.3.579 (Feb. 2000).
43. Warren, J. J., Pohlhaus, T. J., ***et al.*** Structure of the human MutSalpha DNA lesion recognition complex. eng. ***Molecular Cell* 26,** 579–592. doi:10.1016/j.molcel.2007.04.018 (May 2007).
44. Martomo, S. A., Yang, W. W. & Gearhart, P. J. A role for Msh6 but not Msh3 in somatic hypermutation and class switch recombination. eng. ***The Journal of Experimental Medicine* 200,** 61–68. doi:10.1084/jem.20040691 (July 2004).
45. Schaetzlein, S., Chahwan, R., ***et al.*** Mammalian Exo1 encodes both structural and catalytic functions that play distinct roles in essential biological processes. eng. ***Proceedings of the National Academy of Sciences of the United States of America* 110,** E2470–2479. doi:10.1073/pnas.1308512110 (July 2013).
46. Frieder, D., Larijani, M., Collins, C., Shulman, M. & Martin, A. The concerted action of Msh2 and UNG stimulates somatic hypermutation at A . T base pairs. eng. ***Molecular and Cellular Biology* 29,** 5148–5157. doi:10.1128/MCB.00647-09 (Sept. 2009).
47. Kannouche, P. L., Wing, J. & Lehmann, A. R. Interaction of Human DNA Polymerase η with Monoubiquitinated PCNA: A Possible Mechanism for the Polymerase Switch in Response to DNA Damage. ***Molecular Cell* 14,** 491–500. doi:10.1016/S1097-2765(04)00259-X (May 2004).
48. Liu, D., Keijzers, G. & Rasmussen, L. J. DNA mismatch repair and its many roles in eukaryotic cells. en. ***Mutation Research/Reviews in Mutation Research* 773,** 174–187. doi:10.1016/j.mrrev.2017.07.001 (July 2017).
49. Ouchida, R., Ukai, A., ***et al.*** Genetic analysis reveals an intrinsic property of the germinal cen-

ter B cells to generate A:T mutations. ***DNA Repair* 7,** 1392–1398. doi:10.1016/j.dnarep.2008.04.014 (Aug. 2008).

50. Delbos, F., De Smet, A., ***et al.*** Contribution of DNA polymerase η to immunoglobulin gene hypermutation in the mouse. ***Journal of Experimental Medicine* 201,** 1191–1196. doi:10.1084/jem.20050292 (Apr. 2005).
51. Jansen, J. G., Langerak, P., ***et al.*** Strand-biased defect in C/G transversions in hypermutating immunoglobulin genes in Rev1-deficient mice. eng. ***The Journal of Experimental Medicine* 203,** 319–323. doi:10.1084/jem.20052227 (Feb. 2006).
52. Zeng, X., Winter, D. B., ***et al.*** DNA polymerase η is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. en. ***Nature Immunology* 2,** 537–541. doi:10.1038/88740 (June 2001).
53. Alaggio, R., Amador, C., ***et al.*** The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. en. ***Leukemia* 36.** number: 7 publisher: Nature Publishing Group, 1720–1748. doi:10.1038/s41375-022-01620-2 (July 2022).
54. Kurz, K. S., Kalmbach, S., ***et al.*** Follicular Lymphoma in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Biological Data. ***Cancers* 15,** 785. doi:10.3390/cancers15030785 (Jan. 2023).
55. Carbone, A., Roulland, S., ***et al.*** Follicular lymphoma. en. ***Nature Reviews Disease Primers* 5,** 83. doi:10.1038/s41572-019-0132-x (Dec. 2019).
56. Morton, L. M., Wang, S. S., ***et al.*** Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. ***Blood* 107,** 265–276. doi:10.1182/blood-2005-06-2508 (Jan. 2006).
57. Batlevi, C. L., Sha, F., ***et al.*** Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. en. ***Blood Cancer Journal* 10.** number: 7 publisher: Nature Publishing Group, 1–12. doi:10.1038/s41408-020-00340-z (July 17, 2020).
58. Shikata, H., Yakushijin, Y., ***et al.*** Role of activation-induced cytidine deaminase in the progression of follicular lymphoma. en. ***Cancer Science* 103.** _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1349-7006.2011.02186.x, 415–421. doi:10.1111/j.1349-7006.2011.02186.x (2012).
59. Cleary, M. L. & Sklar, J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. ***Proceedings of the National Academy of Sciences* 82.** Publisher: Proceedings of the National Academy of Sciences, 7439–7443. doi:10.1073/pnas.82.21.7439 (Nov. 1985).
60. Tsujimoto, Y., Cossman, J., Jaffe, E. & Croce, C. M. Involvement of the bcl-2 Gene in Human Follicular Lymphoma. ***Science* 228.** Publisher: American Association for the Advancement of Science, 1440–1443. doi:10.1126/science.3874430 (June 1985).
61. Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and malignancy. en. ***Nature Reviews Immunology* 8.** Number: 1 Publisher: Nature Publishing Group, 22–33. doi:10.1038/nri2217 (Jan. 2008).
62. Dickerson, S. K., Market, E., Besmer, E. & Papavasiliou, F. N. AID mediates hypermutation by deaminating single stranded DNA. eng. ***The Journal of Experimental Medicine* 197,** 1291–1296. doi:10.1084/jem.20030481 (May 2003).
63. Muramatsu, M., Sankaranand, V. S., ***et al.*** Specific Expression of Activation-induced Cytidine Deaminase (AID), a Novel Member of the RNA-editing Deaminase Family in Germinal Center B Cells *. English. ***Journal of Biological Chemistry* 274,** 18470–18476. doi:10.1074/jbc.274.26.18470 (June 1999).
64. Kranich, J. & Krautler, N. J. How Follicular Dendritic Cells Shape the B-Cell Antigenome. ***Frontiers in Immunology* 7** (2016).
65. Krysiak, K., Gomez, F., ***et al.*** Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. en. ***Blood* 129,** 473–483. doi:10.1182/blood-2016-07-729954 (Jan. 2017).
66. Okosun, J., Wolfson, R. L., ***et al.*** Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. ***Nature Genetics* 48,** 183–188. doi:10.1038/ng.3473 (Dec. 2015).
67. Perrett, M., Edmondson, C. & Okosun, J. Biology of follicular lymphoma: insights and windows of clinical opportunity. ***Hematology* 2022,** 688–

694. doi:10.1182/hematology.2022000361 (Dec. 2022).

68. Morin, R. D., Mendez-Lago, M., ***et al.*** Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. en. ***Nature* 476.** Number: 7360 Publisher: Nature Publishing Group, 298–303. doi:10.1038/nature10351 (Aug. 2011).
69. Amé-Thomas, P., Le Priol, J., ***et al.*** Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. ***Leukemia* 26,** 1053–1063. doi:10.1038/leu.2011.301 (May 2012).
70. Pangault, C., Amé-Thomas, P., ***et al.*** Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse. ***Cancers* 12,** 2865. doi:10.3390/cancers12102865 (Oct. 2020).
71. Yang, Z.-Z., Kim, H. J., ***et al.*** Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. eng. ***Cell Reports* 26,** 2178–2193.e3. doi:10.1016/j.celrep.2019.01.085 (Feb. 2019).
72. Amé-Thomas, P., Maby-El Hajjami, H., ***et al.*** Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. ***Blood* 109,** 693–702. doi:10.1182/blood-2006-05-020800 (Sept. 2006).
73. Hallek, M., Shanafelt, T. D. & Eichhorst, B. Chronic lymphocytic leukaemia. English. ***The Lancet* 391.** Publisher: Elsevier, 1524–1537. doi:10.1016/S0140-6736(18)30422-7 (Apr. 2018).
74. Delgado, J., Nadeu, F., Colomer, D. & Campo, E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. ***Haematologica* 105,** 2205–2217. doi:10.3324/haematol.2019.236000 (July 2020).
75. Seifert, M., Sellmann, L., ***et al.*** Cellular origin and pathophysiology of chronic lymphocytic leukemia. eng. ***The Journal of Experimental Medicine* 209,** 2183–2198. doi:10.1084/jem.20120833 (Nov. 2012).
76. Landgren, O., Albitar, M., ***et al.*** B-cell clones as early markers for chronic lymphocytic leukemia. eng. ***The New England Journal of Medicine* 360,** 659–667. doi:10.1056/NEJMoa0806122 (Feb. 2009).
77. Rawstron, A. C., Yuille, M. R., ***et al.*** Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. ***Blood* 100,** 2289–2290. doi:10.1182/blood-2002-03-0892 (Oct. 2002).
78. Rawstron, A. C., Bennett, F. L., ***et al.*** Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. eng. ***The New England Journal of Medicine* 359,** 575–583. doi:10.1056/NEJMoa075290 (Aug. 2008).
79. Berndt, S. I., Camp, N. J., ***et al.*** Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. en. ***Nature Communications* 7.** Number: 1 Publisher: Nature Publishing Group, 10933. doi:10.1038/ncomms10933 (Mar. 2016).
80. Speedy, H. E., Beekman, R., ***et al.*** Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. eng. ***Nature Communications* 10,** 3615. doi:10.1038/s41467-019-11582-2 (Aug. 2019).
81. Landau, D. A., Tausch, E., ***et al.*** Mutations driving CLL and their evolution in progression and relapse. en. ***Nature* 526.** Number: 7574 Publisher: Nature Publishing Group, 525–530. doi:10.1038/nature15395 (Oct. 2015).
82. Döhner, H., Stilgenbauer, S., ***et al.*** Genomic aberrations and survival in chronic lymphocytic leukemia. eng. ***The New England Journal of Medicine* 343,** 1910–1916. doi:10.1056/NEJM200012283432602 (Dec. 2000).
83. Nadeu, F., Clot, G., ***et al.*** Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. eng. ***Leukemia* 32,** 645–653. doi:10.1038/leu.2017.291 (Mar. 2018).
84. Dühren-von Minden, M., Übelhart, R., ***et al.*** Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. eng. ***Nature* 489,** 309–312. doi:10.1038/nature11309 (Sept. 2012).
85. Iacovelli, S., Hug, E., ***et al.*** Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. ***Blood* 125,** 1578–1588. doi:10.1182/blood-2014-07-587790 (Mar. 2015).
86. Maity, P. C., Bilal, M., ***et al.*** IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. eng. ***Proceedings of***

the National Academy of Sciences of the United States of America **117,** 4320–4327. doi:10.1073/pnas.1913810117 (Feb. 2020).

87. Stamatopoulos, B., Smith, T., ***et al.*** The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study. eng. ***Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*** **24,** 5048–5057. doi:10.1158/1078-0432.CCR-18-0133 (Oct. 2018).
89. Kinoshita, K. & Honjo, T. Linking class-switch recombination with somatic hypermutation. ***Nat Rev Mol Cell Biol*** **2,** 493–503. doi:10.1038/35080033 (2001).
90. Neuberger, M. S. & Milstein, C. Somatic hypermutation. ***Curr Opin Immunol*** **7,** 248–54. doi:10.1016/0952-7915(95)80010-7 (1995).
91. Papavasiliou, F. N. & Schatz, D. G. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. ***Cell*** **109 Suppl,** S35–44. doi:10.1016/s0092-8674(02)00706-7 (2002).
92. Rajewsky, K. Clonal selection and learning in the antibody system. ***Nature*** **381,** 751–8. doi:10.1038/381751a0 (1996).
93. Seki, M., Gearhart, P. J. & Wood, R. D. DNA polymerases and somatic hypermutation of immunoglobulin genes. ***EMBO Rep*** **6,** 1143–8. doi:10.1038/sj.embor.7400582 (2005).
94. Stavnezer, J., Guikema, J. E. & Schrader, C. E. Mechanism and regulation of class switch recombination. ***Annu Rev Immunol*** **26,** 261–92. doi:10.1146/annurev.immunol.26.021607.090248 (2008).
95. Storb, U., Peters, A., ***et al.*** Molecular aspects of somatic hypermutation of immunoglobulin genes. ***Cold Spring Harb Symp Quant Biol*** **64,** 227–34. doi:10.1101/sqb.1999.64.227 (1999).
96. Muramatsu, M., Sankaranand, V. S., ***et al.*** Specific Expression of Activation-induced Cytidine Deaminase (AID), a Novel Member of the RNA-editing Deaminase Family in Germinal Center B Cells *. English. ***Journal of Biological Chemistry*** **274.** publisher: Elsevier PMID: 10373455, 18470–18476. doi:10.1074/jbc.274.26.18470 (June 25, 1999).
97. Alvarez-Prado, A. F., Perez-Duran, P., ***et al.*** A broad atlas of somatic hypermutation allows prediction of activation-induced deaminase targets. ***J Exp Med*** **215,** 761–771. doi:10.1084/jem.20171738 (2018).
98. Dorner, T., Foster, S. J., Farner, N. L. & Lipsky, P. E. Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. ***Eur J Immunol*** **28,** 3384–96. doi:10.1002/(SICI)1521-4141(199810)28:10<3384::AID-IMMU3384>3.0.CO;2-T (1998).
99. Pilzecker, B. & Jacobs, H. Mutating for Good: DNA Damage Responses During Somatic Hypermutation. ***Front Immunol*** **10,** 438. doi:10.3389/fimmu.2019.00438 (2019).
100. Rogozin, I. B. & Diaz, M. Cutting edge: DGYW/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW/WRCY motif and probably reflects a two-step activation-induced cytidine deaminase-triggered process. ***J Immunol*** **172,** 3382–4. doi:10.4049/jimmunol.172.6.3382 (2004).
101. Rogozin, I. B. & Kolchanov, N. A. Somatic hypermutagenesis in immunoglobulin genes: II. Influence of neighbouring base sequences on mutagenesis. en. ***Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression*** **1171,** 11–18. doi:10.1016/0167-4781(92)90134-L (Nov. 15, 1992).
102. Di Noia, J. & Neuberger, M. S. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. ***Nature*** **419,** 43–8. doi:10.1038/nature00981 (2002).
103. Neuberger, M. S., Di Noia, J. M., ***et al.*** Somatic hypermutation at A.T pairs: polymerase error versus dUTP incorporation. ***Nat Rev Immunol*** **5,** 171–8. doi:10.1038/nri1553 (2005).
104. Rada, C., Di Noia, J. M. & Neuberger, M. S. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. ***Mol Cell*** **16,** 163–71. doi:10.1016/j.molcel.2004.10.011 (2004).
105. Rada, C., Williams, G. T., ***et al.*** Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. ***Curr Biol*** **12,** 1748–55. doi:10.1016/S0960-9822(02)01215-0 (2002).
106. Wiesendanger, M., Kneitz, B., Edelmann, W. & Scharff, M. D. Somatic hypermutation in MutS homologue (MSH)3-, MSH6-, and MSH3/MSH6-

deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. *J Exp Med* **191,** 579–84. doi:10.1084/jem.191.3.579 (2000).

107. Jansen, J. G., Langerak, P., ***et al.*** Strand-biased defect in C/G transversions in hypermutating immunoglobulin genes in Rev1-deficient mice. *J Exp Med* **203,** 319–23. doi:10.1084/jem.20052227 (2006).
108. Krijger, P. H., Tsaalbi-Shtylik, A., ***et al.*** Rev1 is essential in generating G to C transversions downstream of the Ung2 pathway but not the Msh2+Ung2 hybrid pathway. *Eur J Immunol* **43,** 2765–70. doi:10.1002/eji.201243191 (2013).
109. Tissier, A., Kannouche, P., ***et al.*** Co-localization in replication foci and interaction of human Y-family members, DNA polymerase pol eta and REVl protein. *DNA Repair (Amst)* **3,** 1503–14. doi:10.1016/j.dnarep.2004.06.015 (2004).
110. Delbos, F., Aoufouchi, S., Faili, A., Weill, J. C. & Reynaud, C. A. DNA polymerase eta is the sole contributor of A/T modifications during immunoglobulin gene hypermutation in the mouse. *J Exp Med* **204,** 17–23. doi:10.1084/jem.20062131 (2007).
111. Krijger, P. H., Langerak, P., van den Berk, P. C. & Jacobs, H. Dependence of nucleotide substitutions on Ung2, Msh2, and PCNA-Ub during somatic hypermutation. *J Exp Med* **206,** 2603–11. doi:10.1084/jem.20091707 (2009).
112. Langerak, P., Nygren, A. O., Krijger, P. H., van den Berk, P. C. & Jacobs, H. A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification. *J Exp Med* **204,** 1989–98. doi:10.1084/jem.20070902 (2007).
113. Zeng, X., Winter, D. B., ***et al.*** DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. *Nat Immunol* **2,** 537–41. doi:10.1038/88740 (2001).
114. Kunkel, T. A. & Erie, D. A. Eukaryotic Mismatch Repair in Relation to DNA Replication. *Annu Rev Genet* **49,** 291–313. doi:10.1146/annurev-genet-112414-054722 (2015).
115. Bardwell, P. D., Woo, C. J., ***et al.*** Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. *Nat Immunol* **5,** 224–9. doi:10.1038/ni1031 (2004).
116. Pena-Diaz, J., Bregenhorn, S., ***et al.*** Noncanonical mismatch repair as a source of genomic instability in human cells. *Mol Cell* **47,** 669–80. doi:10.1016/j.molcel.2012.07.006 (2012).
117. Rogozin, I. B., Pavlov, Y. I., Bebenek, K., Matsuda, T. & Kunkel, T. A. Somatic mutation hotspots correlate with DNA polymerase eta error spectrum. *Nat Immunol* **2,** 530–6. doi:10.1038/88732 (2001).
118. Wilson, T. M., Vaisman, A., ***et al.*** MSH2-MSH6 stimulates DNA polymerase eta, suggesting a role for A:T mutations in antibody genes. *J Exp Med* **201,** 637–45. doi:10.1084/jem.20042066 (2005).
119. Krijger, P. H., van den Berk, P. C., ***et al.*** PCNA ubiquitination-independent activation of polymerase eta during somatic hypermutation and DNA damage tolerance. *DNA Repair (Amst)* **10,** 1051–9. doi:10.1016/j.dnarep.2011.08.005 (2011).
120. Martomo, S. A., Yang, W. W., ***et al.*** Different mutation signatures in DNA polymerase eta- and MSH6-deficient mice suggest separate roles in antibody diversification. *Proc Natl Acad Sci U S A* **102,** 8656–61. doi:10.1073/pnas.0501852102 (2005).
121. Sale, J. E., Lehmann, A. R. & Woodgate, R. Y-family DNA polymerases and their role in tolerance of cellular DNA damage. *Nat Rev Mol Cell Biol* **13,** 141–52. doi:10.1038/nrm3289 (2012).
122. Maul, R. W., MacCarthy, T., ***et al.*** DNA polymerase iota functions in the generation of tandem mutations during somatic hypermutation of antibody genes. *J Exp Med* **213,** 1675–83. doi:10.1084/jem.20151227 (2016).
123. Lee, S. S., Tranchina, D., Ohta, Y., Flajnik, M. F. & Hsu, E. Hypermutation in shark immunoglobulin light chain genes results in contiguous substitutions. *Immunity* **16,** 571–82. doi:10.1016/S1074-7613(02)00300-X (2002).
124. Malecek, K., Brandman, J., ***et al.*** Somatic hypermutation and junctional diversification at Ig heavy chain loci in the nurse shark. *J Immunol* **175,** 8105–15. doi:10.4049/jimmunol.175.12.8105 (2005).
125. Chen, J. M., Cooper, D. N. & Ferec, C. A new and more accurate estimate of the rate of concurrent tandem-base substitution mutations in the human germline: 0.4% of the single-nucleotide

substitution mutation rate. ***Hum Mutat* 35,** 392–4. doi:10.1002/humu.22501 (2014).

126. Francioli, L. C., Polak, P. P., ***et al.*** Genome-wide patterns and properties of de novo mutations in humans. ***Nat Genet* 47,** 822–826. doi:10.1038/ng.3292 (2015).
127. Harris, K. & Nielsen, R. Error-prone polymerase activity causes multinucleotide mutations in humans. ***Genome Res* 24,** 1445–54. doi:10.1101/gr.170696.113 (2014).
128. Schrider, D. R., Hourmozdi, J. N. & Hahn, M. W. Pervasive multinucleotide mutational events in eukaryotes. ***Curr Biol* 21,** 1051–4. doi:10.1016/j.cub.2011.05.013 (2011).
129. Saribasak, H., Maul, R. W., ***et al.*** DNA polymerase zeta generates tandem mutations in immunoglobulin variable regions. ***J Exp Med* 209,** 1075–81. doi:10.1084/jem.20112234 (2012).
130. Alexandrov, L. B., Kim, J., ***et al.*** The Repertoire of Mutational Signatures in Human Cancer. ***bioRxiv,*** 322859. doi:10.1101/322859 (2018).
131. Koning, M. T., Kielbasa, S. M., ***et al.*** ARTISAN PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding bias. ***Br J Haematol* 178,** 983–986. doi:10.1111/bjh.14180 (2017).
132. Koning, M. T., Trollmann, I. J. M., ***et al.*** Peripheral IgE Repertoires of Healthy Donors Carry Moderate Mutation Loads and Do Not Overlap With Other Isotypes. ***Front Immunol* 10,** 1543. doi:10.3389/fimmu.2019.01543 (2019).
133. Alamyar, E., Duroux, P., Lefranc, M. P. & Giudicelli, V. IMGT((R)) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. ***Methods Mol Biol* 882,** 569–604. doi:10.1007/978-1-61779-842-9_32 (2012).
134. IJspeert, H., van Schouwenburg, P. A., ***et al.*** Repertoire Sequencing of B Cells Elucidates the Role of UNG and Mismatch Repair Proteins in Somatic Hypermutation in Humans. ***Front Immunol* 10,** 1913. doi:10.3389/fimmu.2019.01913 (2019).
135. IJspeert, H., van Schouwenburg, P. A., ***et al.*** Evaluation of the Antigen-Experienced B-Cell Receptor Repertoire in Healthy Children and Adults. ***Front Immunol* 7,** 410. doi:10.3389/fimmu.2016.00410 (2016).
136. Driessen, G. J., Ijspeert, H., ***et al.*** Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. ***J Allergy Clin Immunol* 131,** 1367–75 e9. doi:10.1016/j.jaci.2013.01.053 (2013).
137. Alexandrov, L. B., Kim, J., ***et al.*** The repertoire of mutational signatures in human cancer. ***Nature* 578,** 94–101. doi:10.1038/s41586-020-1943-3 (2020).
138. R Core Team. ***R: A Language and Environment for Statistical Computing*** R Foundation for Statistical Computing (Vienna, Austria, 2021).
139. Jacobs, H., Fukita, Y., ***et al.*** Hypermutation of immunoglobulin genes in memory B cells of DNA repair-deficient mice. ***J Exp Med* 187,** 1735–43. doi:10.1084/jem.187.11.1735 (1998).
140. Sohail, A., Klapacz, J., Samaranayake, M., Ullah, A. & Bhagwat, A. S. Human activation-induced cytidine deaminase causes transcription-dependent, strand-biased C to U deaminations. ***Nucleic Acids Res* 31,** 2990–4. doi:10.1093/nar/gkg464 (2003).
141. Kasar, S., Kim, J., ***et al.*** Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. ***Nat Commun* 6,** 8866. doi:10.1038/ncomms9866 (2015).
142. Maul, R. W. & Gearhart, P. J. Refining the Neuberger model: Uracil processing by activated B cells. ***Eur J Immunol* 44,** 1913–6. doi:10.1002/eji.201444813 (2014).
143. Tesch, V. K., H, I. J., ***et al.*** No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency. ***Front Immunol* 9,** 1506. doi:10.3389/fimmu.2018.01506 (2018).
144. Wimmer, K., Kratz, C. P., ***et al.*** Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). ***J Med Genet* 51,** 355–65. doi:10.1136/jmedgenet-2014-102284 (2014).
145. Bahjat, M., Stratigopoulou, M., ***et al.*** DNA polymerase β prevents AID-instigated mutagenic non-canonical mismatch DNA repair. ***bioRxiv*** (2020).
146. Zharkov, D. O., Mechetin, G. V. & Nevinsky, G. A. Uracil-DNA glycosylase: Structural, thermodynamic and kinetic aspects of lesion search and

recognition. ***Mutat Res* 685,** 11–20. doi:10.1016/j.mrfmmm.2009.10.017 (2010).

147. Corbella, M., Voityuk, A. A. & Curutchet, C. How abasic sites impact hole transfer dynamics in GC-rich DNA sequences. ***Phys Chem Chem Phys* 20,** 23123–23131. doi:10.1039/c8cp03572e (2018).
148. Yin, Y., Yang, L., ***et al.*** Dynamics of spontaneous flipping of a mismatched base in DNA duplex. ***Proc Natl Acad Sci U S A* 111,** 8043–8. doi:10.1073/pnas.1400667111 (2014).
149. Cao, C., Jiang, Y. L., Stivers, J. T. & Song, F. Dynamic opening of DNA during the enzymatic search for a damaged base. ***Nat Struct Mol Biol* 11,** 1230–6. doi:10.1038/nsmb864 (2004).
150. Carr, C. E., Khutsishvili, I., Gold, B. & Marky, L. A. Thermodynamic Stability of DNA Duplexes Comprising the Simplest T –> dU Substitutions. ***Biochemistry* 57,** 5666–5671. doi:10.1021/acs.biochem.8b00676 (2018).
151. Parker, J. B., Bianchet, M. A., ***et al.*** Enzymatic capture of an extrahelical thymine in the search for uracil in DNA. ***Nature* 449,** 433–7. doi:10.1038/nature06131 (2007).
152. Fuxreiter, M., Luo, N., Jedlovszky, P., Simon, I. & Osman, R. Role of base flipping in specific recognition of damaged DNA by repair enzymes. ***J Mol Biol* 323,** 823–34. doi:10.1016/s0022-2836(02)00999-3 (2002).
153. Imhof, P. & Zahran, M. The effect of a G:T mispair on the dynamics of DNA. ***PLoS One* 8,** e53305. doi:10.1371/journal.pone.0053305 (2013).
154. Varnai, P., Canalia, M. & Leroy, J. L. Opening mechanism of G.T/U pairs in DNA and RNA duplexes: a combined study of imino proton exchange and molecular dynamics simulation. ***J Am Chem Soc* 126,** 14659–67. doi:10.1021/ja0470721 (2004).
155. Chen, J. M., Ferec, C. & Cooper, D. N. Patterns and mutational signatures of tandem base substitutions causing human inherited disease. ***Hum Mutat* 34,** 1119–30. doi:10.1002/humu.22341 (2013).
156. Stone, J. E., Lujan, S. A., Kunkel, T. A. & Kunkel, T. A. DNA polymerase zeta generates clustered mutations during bypass of endogenous DNA lesions in Saccharomyces cerevisiae. ***Environ Mol Mutagen* 53,** 777–86. doi:10.1002/em.21728 (2012).
157. Faili, A., Aoufouchi, S., ***et al.*** Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota. ***Nature* 419,** 944–7. doi:10.1038/nature01117 (2002).
158. Weill, J. C. & Reynaud, C. A. DNA polymerases in adaptive immunity. ***Nat Rev Immunol* 8,** 302–12. doi:10.1038/nri2281 (2008).
159. Biertumpfel, C., Zhao, Y., ***et al.*** Structure and mechanism of human DNA polymerase eta. ***Nature* 465,** 1044–8. doi:10.1038/nature09196 (2010).
160. Matsuda, T., Bebenek, K., ***et al.*** Error rate and specificity of human and murine DNA polymerase eta. ***J Mol Biol* 312,** 335–46. doi:10.1006/jmbi.2001.4937 (2001).
161. Davies, E. G. & Thrasher, A. J. Update on the hyper immunoglobulin M syndromes. ***Br J Haematol* 149,** 167–80. doi:10.1111/j.1365-2141.2010.08077.x (2010).
162. Imai, K., Slupphaug, G., ***et al.*** Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. ***Nat Immunol* 4,** 1023–8. doi:10.1038/ni974 (2003).
163. Sepúlveda-Yáñez, J. H., Alvarez-Saravia, D., ***et al.*** ***Detection of occurrent somatic hypermutation and associated gene expression profile in single*** Manuscript submitted for publication.
164. Pavri, R. & Nussenzweig, M. C. en. in ***Advances in Immunology*** (eds Alt, F. W., Austen, K. F., ***et al.***) DOI: 10.1016/B978-0-12-387663-8.00005-3, 1–26 (Academic Press, Jan. 1, 2011).
165. Rada, C. & Milstein, C. The intrinsic hypermutability of antibody heavy and light chain genes decays exponentially. eng. ***The EMBO journal* 20.** PMID: 11500383 PMCID: PMC125579, 4570–4576. doi:10.1093/emboj/20.16.4570 (Aug. 15, 2001).
166. Rajewsky, K., Förster, I. & Cumano, A. Evolutionary and somatic selection of the antibody repertoire in the mouse. eng. ***Science (New York, N.Y.)* 238.** PMID: 3317826, 1088–1094. doi:10.1126/science.3317826 (Nov. 20, 1987).
167. Hardianti, M. S., Tatsumi, E., ***et al.*** Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL. ***Leukemia* 18,** 826–831. doi:10.1038/sj.leu.2403323 (Apr. 2004).

168. Noppe, S. M., Heirman, C., ***et al.*** The genetic variability of the VH genes in follicular lymphoma: the impact of the hypermutation mechanism. en. ***British Journal of Haematology*** **107,** 625–640. doi:10.1046/j.1365-2141.1999.01732.x (1999).
169. Scherer, F., Navarrete, M. A., ***et al.*** Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation. en. ***Leukemia & Lymphoma*** **57,** 151–160. doi:10.3109/10428194.2015.1037758 (Jan. 2, 2016).
170. Zuckerman, N. S., McCann, K. J., ***et al.*** Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. ***International Immunology*** **22,** 875–887. doi:10.1093/intimm/dxq441 (Nov. 1, 2010).
171. Hao, Y., Hao, S., ***et al.*** Integrated analysis of multimodal single-cell data. English. ***Cell*** **184.** publisher: Elsevier PMID: 34062119, 3573–3587.e29. doi:10.1016/j.cell.2021.04.048 (June 24, 2021).
172. Germain, P.-L., Lun, A., Meixide, C. G., Macnair, W. & Robinson, M. D. ***Doublet identification in single-cell sequencing data using scDblFinder*** en. Tech. rep. DOI: 10.12688/f1000research.73600.2 type: article (May 16, 2022).
173. Li, H. New strategies to improve minimap2 alignment accuracy. ***Bioinformatics*** **37,** 4572–4574. doi:10.1093/bioinformatics/btab705 (Dec. 1, 2021).
174. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. ***Genome Biology*** **15,** 550. doi:10.1186/s13059-014-0550-8 (Dec. 5, 2014).
175. L. Lun, A. T., Bach, K. & Marioni, J. C. Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. ***Genome Biology*** **17,** 75. doi:10.1186/s13059-016-0947-7 (Apr. 27, 2016).
176. Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. ***Nucleic Acids Research*** **51,** D587–D592. doi:10.1093/nar/gkac963 (Jan. 6, 2023).
177. Wu, T., Hu, E., ***et al.*** clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. English. ***The Innovation*** **2.** publisher: Elsevier PMID: 34557778. doi:10.1016/j.xinn.2021.100141 (Aug. 28, 2021).
178. Petersen-Mahrt, S. K., Harris, R. S. & Neuberger, M. S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. en. ***Nature*** **418.** number: 6893 publisher: Nature Publishing Group, 99–104. doi:10.1038/nature00862 (July 2002).
179. Rada, C., Di Noia, J. M. & Neuberger, M. S. Mismatch Recognition and Uracil Excision Provide Complementary Paths to Both Ig Switching and the A/T-Focused Phase of Somatic Mutation. en. ***Molecular Cell*** **16,** 163–171. doi:10.1016/j.molcel.2004.10.011 (Oct. 22, 2004).
180. Shen, H. M., Tanaka, A., Bozek, G., Nicolae, D. & Storb, U. Somatic Hypermutation and Class Switch Recombination in Msh6-/-Ung-/- Double-Knockout Mice1. ***The Journal of Immunology*** **177,** 5386–5392. doi:10.4049/jimmunol.177.8.5386 (Oct. 15, 2006).
181. Sepulveda-Yanez, J. H., Alvarez-Saravia, D., ***et al.*** Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas. en. ***International Journal of Molecular Sciences*** **22.** number: 23 publisher: Multidisciplinary Digital Publishing Institute, 13015. doi:10.3390/ijms222313015 (Jan. 2021).
182. Rogozin, I. B., Pavlov, Y. I., Bebenek, K., Matsuda, T. & Kunkel, T. A. Somatic mutation hotspots correlate with DNA polymerase η error spectrum. en. ***Nature Immunology*** **2.** number: 6 publisher: Nature Publishing Group, 530–536. doi:10.1038/88732 (June 2001).
183. Tang, C., Bagnara, D., Chiorazzi, N., Scharff, M. D. & MacCarthy, T. AID Overlapping and Polη Hotspots Are Key Features of Evolutionary Variation Within the Human Antibody Heavy Chain (IGHV) Genes. ***Frontiers in Immunology*** **11.** [Online; accessed 2024-01-05] (2020).
184. Rogozin, I. B., Lada, A. G., ***et al.*** Activation induced deaminase mutational signature overlaps with CpG methylation sites in follicular lymphoma and other cancers. ***Scientific Reports*** **6,** 38133. doi:10.1038/srep38133 (Dec. 7, 2016).
185. Genovese, C. & Milcarek, C. Increased half-life of mu immunoglobulin mRNA during mouse B cell development increases its abundancy. eng. ***Molecular Immunology*** **27.** PMID: 2119479,

733–743. doi:10.1016/0161-5890(90)90082-b (Aug. 1990).

186. Mason, J. O., Williams, G. T. & Neuberger, M. S. The half-life of immunoglobulin mRNA increases during B-cell differentiation: a possible role for targeting to membrane-bound polysomes. en. ***Genes & Development,*** 1003–1011. doi:10.1101/gad.2.8.1003 (Aug. 1988).
187. Nagaoka, H., Muramatsu, M., Yamamura, N., Kinoshita, K. & Honjo, T. Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. eng. ***The Journal of Experimental Medicine*** **195.** PMID: 11854365 PMCID: PMC2193625, 529–534. doi:10.1084/jem.20012144 (Feb. 18, 2002).
188. Wilson, T. M., Vaisman, A., ***et al.*** MSH2–MSH6 stimulates DNA polymerase η, suggesting a role for A:T mutations in antibody genes. ***Journal of Experimental Medicine*** **201,** 637–645. doi:10.1084/jem.20042066 (Feb. 14, 2005).
189. Rada, C., Williams, G. T., ***et al.*** Immunoglobulin Isotype Switching Is Inhibited and Somatic Hypermutation Perturbed in UNG-Deficient Mice. en. ***Current Biology*** **12,** 1748–1755. doi:10.1016/S0960-9822(02)01215-0 (Oct. 2002).
190. Chahwan, R., Edelmann, W., Scharff, M. D. & Roa, S. AIDing antibody diversity by error-prone mismatch repair. ***Seminars in immunology*** **24.** PMID: 22703640 PMCID: PMC3422444, 293–300. doi:10.1016/j.smim.2012.05.005 (Aug. 2012).
191. Seifert, M., Sellmann, L., ***et al.*** Cellular origin and pathophysiology of chronic lymphocytic leukemia. eng. ***The Journal of Experimental Medicine*** **209.** PMID: 23091163 PMCID: PMC3501361, 2183–2198. doi:10.1084/jem.20120833 (Nov. 19, 2012).
192. Pilzecker, B. & Jacobs, H. Mutating for Good: DNA Damage Responses During Somatic Hypermutation. ***Frontiers in Immunology*** **10.** [Online; accessed 2024-01-22] (2019).
193. Senavirathne, G., Bertram, J. G., ***et al.*** Activation-induced deoxycytidine deaminase (AID) co-transcriptional scanning at single-molecule resolution. ***Nature Communications*** **6.** PMID: 26681117 PMCID: PMC4703863, 10209. doi:10.1038/ncomms10209 (Dec. 18, 2015).
194. Zahn, A., Eranki, A. K., ***et al.*** Activation induced deaminase C-terminal domain links DNA breaks to end protection and repair during class switch recombination. en. ***Proceedings of the National Academy of Sciences*** **111.** [Online; accessed 2024-01-04]. doi:10.1073/pnas.1320486111 (Mar. 18, 2014).
195. Xu, Z., Zan, H., Pal, Z. & Casali, P. DNA REPLICATION TO AID SOMATIC HYPERMUTATION. ***Advances in experimental medicine and biology*** **596.** PMID: 17338180 PMCID: PMC3140876, 111–127. doi:10.1007/0-387-46530-8_10 (2007).
196. Victora, G. D., Dominguez-Sola, D., ***et al.*** Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. ***Blood*** **120,** 2240–2248. doi:10.1182/blood-2012-03-415380 (Sept. 13, 2012).
197. Basso, K., Klein, U., ***et al.*** Tracking CD40 signaling during germinal center development. en. ***Blood*** **104,** 4088–4096. doi:10.1182/blood-2003-12-4291 (Dec. 15, 2004).
198. Gehringer, F., Weissinger, S. E., ***et al.*** FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma. ***Cancers*** **11.** PMID: 31557894 PMCID: PMC6826697, 1427. doi:10.3390/cancers11101427 (Sept. 25, 2019).
199. Wood, R. D., Gearhart, P. J., Neuberger, M. S., Tippin, B. & Goodman, M. F. A new class of errant DNA polymerases provides candidates for somatic hypermutation. ***Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences*** **356.** publisher: Royal Society, 47–51. doi:10.1098/rstb.2000.0747 (Jan. 29, 2001).
200. Lehmann, A. R., Niimi, A., ***et al.*** Translesion synthesis: Y-family polymerases and the polymerase switch. eng. ***DNA repair*** **6.** PMID: 17363342, 891–899. doi:10.1016/j.dnarep.2007.02.003 (July 1, 2007).
201. Biertümpfel, C., Zhao, Y., ***et al.*** Structure and mechanism of human DNA polymerase η. en. ***Nature*** **465.** number: 7301 publisher: Nature Publishing Group, 1044–1048. doi:10.1038/nature09196 (June 2010).
202. Sale, J. E. Translesion DNA Synthesis and Mutagenesis in Eukaryotes. en. ***Cold Spring Harbor Perspectives in Biology*** **5.** Company: Cold Spring Harbor Laboratory Press Distributor:

Cold Spring Harbor Laboratory Press Institution: Cold Spring Harbor Laboratory Press Label: Cold Spring Harbor Laboratory Press publisher: Cold Spring Harbor Lab PMID: 23457261, a012708. doi:10.1101/cshperspect.a012708 (Mar. 1, 2013).

203. Lohr, J. G., Stojanov, P., *et al.* Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. ***Proceedings of the National Academy of Sciences* 109.** publisher: Proceedings of the National Academy of Sciences, 3879–3884. doi:10.1073/pnas.1121343109 (Mar. 6, 2012).
204. Morande, P. E., Yan, X.-J., *et al.* AID overexpression leads to aggressive murine CLL and non-immunoglobulin mutations that mirror human neoplasms. ***Blood* 138,** 246–258. doi:10.1182/blood.2020008654 (July 22, 2021).
206. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. ***Cell* 144,** 646–74. doi:10.1016/j.cell.2011.02.013 (2011).
207. Hainaut, P. & Pfeifer, G. P. Patterns of p53 G–>T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. ***Carcinogenesis* 22,** 367–74. doi:10.1093/carcin/22.3.367 (2001).
208. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. ***Nature* 458,** 719–24. doi:10.1038/nature07943 (2009).
209. Alexandrov, L. B., Nik-Zainal, S., *et al.* Signatures of mutational processes in human cancer. ***Nature* 500,** 415–21. doi:10.1038/nature12477 (2013).
210. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. ***Cell Rep* 3,** 246–59. doi:10.1016/j.celrep.2012.12.008 (2013).
211. Petersen-Mahrt, S. K., Harris, R. S. & Neuberger, M. S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. ***Nature* 418,** 99–103. doi:10.1038/nature00862 (2002).
212. Winter, D. B. & Gearhart, P. J. Altered spectra of hypermutation in DNA repair-deficient mice. ***Philos Trans R Soc Lond B Biol Sci* 356,** 5–11. doi:10.1098/rstb.2000.0742 (2001).
213. Rogozin, I. B., Lada, A. G., *et al.* Activation induced deaminase mutational signature overlaps with CpG methylation sites in follicular lymphoma and other cancers. ***Sci Rep* 6,** 38133. doi:10.1038/srep38133 (2016).
214. Qian, J., Wang, Q., *et al.* B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. ***Cell* 159,** 1524–37. doi:10.1016/j.cell.2014.11.013 (2014).
215. Lieberman-Aiden, E., van Berkum, N. L., *et al.* Comprehensive mapping of long-range interactions reveals folding principles of the human genome. ***Science* 326,** 289–93. doi:10.1126/science.1181369 (2009).
216. Rao, S. S., Huntley, M. H., *et al.* A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. ***Cell* 159,** 1665–80. doi:10.1016/j.cell.2014.11.021 (2014).
217. Teras, L. R., DeSantis, C. E., *et al.* 2016 US lymphoid malignancy statistics by World Health Organization subtypes. ***CA Cancer J Clin* 66,** 443–459. doi:10.3322/caac.21357 (2016).
218. Scherer, F., van der Burgt, M., *et al.* Selection patterns of B-cell receptors and the natural history of follicular lymphoma. ***Br J Haematol* 175,** 972–975. doi:10.1111/bjh.13901 (2016).
219. Scherer, F., Navarrete, M. A., *et al.* Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation. ***Leuk Lymphoma* 57,** 151–60. doi:10.3109/10428194.2015.1037758 (2016).
220. Oppezzo, P., Vuillier, F., *et al.* Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. ***Blood* 101,** 4029–4032. doi:10.1182/blood-2002-10-3175 (2003).
221. Burns, A., Alsolami, R., *et al.* Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups. ***Leukemia* 32,** 332–342. doi:10.1038/leu.2017.177 (2018).
222. Lappalainen, I., Almeida-King, J., *et al.* The European Genome-phenome Archive of human data consented for biomedical research. ***Nat Genet* 47,** 692–5. doi:10.1038/ng.3312 (2015).
223. Okosun, J., Wolfson, R. L., *et al.* Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. ***Nat Genet* 48,** 183–8. doi:10.1038/ng.3473 (2016).

224. Damm, F., Mylonas, E., ***et al.*** Acquired initiating mutations in early hematopoietic cells of CLL patients. ***Cancer Discov*** **4,** 1088–101. doi:10.1158/2159-8290.CD-14-0104 (2014).
225. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. ***Bioinformatics*** **25,** 1754–60. doi:10.1093/bioinformatics/btp324 (2009).
226. McKenna, A., Hanna, M., ***et al.*** The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. ***Genome Res*** **20,** 1297–303. doi:10.1101/gr.107524.110 (2010).
227. Koboldt, D. C., Zhang, Q., ***et al.*** VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. ***Genome Res*** **22,** 568–76. doi:10.1101/gr.129684.111 (2012).
228. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. ***Nucleic Acids Res*** **38,** e164. doi:10.1093/nar/gkq603 (2010).
229. Genomes Project, C., Auton, A., ***et al.*** A global reference for human genetic variation. ***Nature*** **526,** 68–74. doi:10.1038/nature15393 (2015).
230. Lek, M., Karczewski, K. J., ***et al.*** Analysis of protein-coding genetic variation in 60,706 humans. ***Nature*** **536,** 285–91. doi:10.1038/nature19057 (2016).
231. Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense predictions for genomes. ***Nat Protoc*** **11,** 1–9. doi:10.1038/nprot.2015.123 (2016).
232. Chun, S. & Fay, J. C. Identification of deleterious mutations within three human genomes. ***Genome Res*** **19,** 1553–61. doi:10.1101/gr.092619.109 (2009).
233. Andrews, S., Krueger, F., ***et al.*** ***FastQC*** 2010.
234. Bergstrom, E. N., Huang, M. N., ***et al.*** SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. ***BMC Genomics*** **20,** 685. doi:10.1186/s12864-019-6041-2 (2019).
235. Tate, J. G., Bamford, S., ***et al.*** COSMIC: the Catalogue Of Somatic Mutations In Cancer. ***Nucleic Acids Res*** **47,** D941–D947. doi:10.1093/nar/gky1015 (2019).
236. Virtanen, P., Gommers, R., ***et al.*** SciPy 1.0: fundamental algorithms for scientific computing in Python. ***Nat Methods*** **17,** 261–272. doi:10.1038/s41592-019-0686-2 (2020).
237. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. ***Genome Biol*** **17,** 31. doi:10.1186/s13059-016-0893-4 (2016).
238. Lawson, R. G. & Jurs, P. C. New Index for Clustering Tendency and Its Application to Chemical Problems. ***Journal of Chemical Information and Computer Sciences*** **30,** 36–41. doi:DOI10.1021/ci00065a010 (1990).
239. Kaufman, L. & Rousseeuw, P. ***Finding Groups in Data: An Introduction to Cluster Analysis*** (John Wiley & Sons, 2009).
240. Lê, S., Josse, J. & Husson, F. FactoMineR: AnR-Package for Multivariate Analysis. ***Journal of Statistical Software*** **25,** Journal of Statistical Software. doi:10.18637/jss.v025.i01 (2008).
241. Xiong, K. & Ma, J. Revealing Hi-C subcompartments by imputing inter-chromosomal chromatin interactions. ***Nat Commun*** **10,** 5069. doi:10.1038/s41467-019-12954-4 (2019).
242. Pedersen, B. S., Layer, R. M. & Quinlan, A. R. Vcfanno: fast, flexible annotation of genetic variants. ***Genome biology*** **17,** 1–9. doi:10.1186/s13059-016-0973-5 (2016).
243. Methot, S. P. & Di Noia, J. M. Molecular Mechanisms of Somatic Hypermutation and Class Switch Recombination. ***Adv Immunol*** **133,** 37–87. doi:10.1016/bs.ai.2016.11.002 (2017).
244. Jansen, H., Verhoeven, A. J., ***et al.*** Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. ***Arterioscler Thromb Vasc Biol*** **17,** 2837–42. doi:10.1161/01.atv.17.11.2837 (1997).
245. Cancer Genome Atlas Research, N., Weinstein, J. N., ***et al.*** The Cancer Genome Atlas Pan-Cancer analysis project. ***Nat Genet*** **45,** 1113–20. doi:10.1038/ng.2764 (2013).
246. Maura, F., Degasperi, A., ***et al.*** A practical guide for mutational signature analysis in hematological malignancies. ***Nature communications*** **10,** 2969. doi:10.1038/s41467-019-11037-8 (2019).
247. Das, R. & Ghosh, S. K. Genetic variants of the DNA repair genes from Exome Aggregation Consortium (EXAC) database: significance in cancer.

DNA Repair (Amst) **52,** 92–102. doi:10.1016/j.dnarep.2017.02.013 (2017).

248. Tsukamoto, T., Nakano, M., ***et al.*** High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif. ***Sci Rep*** **7,** 14039. doi:10.1038/s41598-017-14150-0 (2017).
249. Jia, P., Pao, W. & Zhao, Z. Patterns and processes of somatic mutations in nine major cancers. ***BMC Med Genomics*** **7,** 11. doi:10.1186/1755-8794-7-11 (2014).
250. Lee, D. D. & Seung, H. S. Learning the parts of objects by non-negative matrix factorization. ***Nature*** **401,** 788–91. doi:10.1038/44565 (1999).
251. Alexandrov, L. B., Jones, P. H., ***et al.*** Clock-like mutational processes in human somatic cells. ***Nat Genet*** **47,** 1402–7. doi:10.1038/ng.3441 (2015).
252. Meng, F. L., Du, Z., ***et al.*** Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. ***Cell*** **159,** 1538–48. doi:10.1016/j.cell.2014.11.014 (2014).
253. Pasqualucci, L., Guglielmino, R., ***et al.*** Expression of the AID protein in normal and neoplastic B cells. ***Blood*** **104,** 3318–25. doi:10.1182/blood-2004-04-1558 (2004).
254. Nagai, L. A. E., Park, S. J. & Nakai, K. Analyzing the 3D chromatin organization coordinating with gene expression regulation in B-cell lymphoma. ***BMC Med Genomics*** **11,** 127. doi:10.1186/s12920-018-0437-8 (2019).
255. Bogliolo, M., Bluteau, D., ***et al.*** Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia. ***Genet Med*** **20,** 458–463. doi:10.1038/gim.2017.124 (2018).
256. Bret, C., Klein, B., ***et al.*** DNA repair in diffuse large B-cell lymphoma: a molecular portrait. ***Br J Haematol*** **169,** 296–9. doi:10.1111/bjh.13206 (2015).
257. Leeksma, O. C., de Miranda, N. F. & Veelken, H. Germline mutations predisposing to diffuse large B-cell lymphoma. ***Blood Cancer J*** **7,** e532. doi:10.1038/bcj.2017.15 (2017).
258. Quinten, E., Sepúlveda-Yáñez, J. H., ***et al.*** Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia. ***Haematologica*** **109.** Section: Articles, 824–834. doi:10.3324/haematol.2022.282542 (July 2023).
259. Hallek, M., Shanafelt, T. D. & Eichhorst, B. Chronic lymphocytic leukaemia. English. ***The Lancet*** **391.** publisher: Elsevier PMID: 29477250, 1524–1537. doi:10.1016/S0140-6736(18)30422-7 (Apr. 14, 2018).
260. Delgado, J., Nadeu, F., Colomer, D. & Campo, E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. ***Haematologica*** **105.** PMID: 33054046 PMCID: PMC7556519, 2205–2217. doi:10.3324/haematol.2019.236000 (July 2, 2020).
261. Slager, S. L., Lanasa, M. C., ***et al.*** Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. ***Blood*** **137,** 2046–2056. doi:10.1182/blood.2020006322 (Apr. 2021).
262. Minici, C., Gounari, M., ***et al.*** Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. eng. ***Nat Commun*** **8,** 15746. doi:10.1038/ncomms15746 (June 2017).
263. Agathangelidis, A., Chatzidimitriou, A., ***et al.*** Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. ***Blood*** **137,** 1365–1376. doi:10.1182/blood.2020007039 (Mar. 2021).
264. Cerhan, J. R. & Slager, S. L. Familial predisposition and genetic risk factors for lymphoma. ***Blood*** **126,** 2265–73. doi:10.1182/blood-2015-04-537498 (Nov. 2015).
265. Kleinstern, G., Camp, N. J., ***et al.*** Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. ***Blood*** **131,** 2541–2551. doi:10.1182/blood-2017-11-814608 (June 2018).
266. Law, P. J., Berndt, S. I., ***et al.*** Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. ***Nat Commun*** **8,** 14175. doi:10.1038/ncomms14175 (Feb. 2017).
267. Agathangelidis, A., Ljungstrom, V., ***et al.*** Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. ***Haematologica*** **103,** 865–873. doi:10.3324/haematol.2017.177212 (May 2018).
268. Koning, M. T., Kielbasa, S. M., ***et al.*** ARTISAN PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding

bias. *Br J Haematol* **178,** 983–986. doi:10.1111/bjh.14180 (Sept. 2017).

269. Koning, M. T., Quinten, E., *et al.* Acquired N-Linked Glycosylation Motifs in B-Cell Receptors of Primary Cutaneous B-Cell Lymphoma and the Normal B-Cell Repertoire. *J Invest Dermatol* **139,** 2195–2203. doi:10.1016/j.jid.2019.04.005 (Oct. 2019).
270. Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. eng. *Nucleic Acids Res* **36,** W503–8. doi:10.1093/nar/gkn316 (July 2008).
271. Giudicelli, V., Brochet, X. & Lefranc, M. P. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. *Cold Spring Harb Protoc* **2011,** 695–715. doi:10.1101/pdb.prot5633 (June 2011).
272. Agathangelidis, A., Darzentas, N., *et al.* Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. *Blood* **119,** 4467–75. doi:10.1182/blood-2011-11-393694 (May 2012).
273. Meixlsperger, S., Kohler, F., *et al.* Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. eng. *Immunity* **26,** 323–33. doi:10.1016/j.immuni.2007.01.012 (Mar. 2007).
274. De Groen, R. A. L., van Eijk, R., *et al.* Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. *Blood Adv* **5,** 3760–3775. doi:10.1182/bloodadvances.2021005215 (Oct. 2021).
275. Pfeifer, D., Pantic, M., *et al.* Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. *Blood* **109,** 1202–10 (Feb. 2007).
276. Berndt, S. I., Skibola, C. F., *et al.* Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nat Genet* **45,** 868–76. doi:10.1038/ng.2652 (Aug. 2013).
277. Crowther-Swanepoel, D., Broderick, P., *et al.* Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. *Nat Genet* **42,** 132–6. doi:10.1038/ng.510 (Feb. 2010).
278. Di Bernardo, M. C., Crowther-Swanepoel, D., *et al.* A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. *Nat Genet* **40,** 1204–10. doi:10.1038/ng.219 (Oct. 2008).
279. Slager, S. L., Rabe, K. G., *et al.* Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. *Blood* **117,** 1911–6. doi:10.1182/blood-2010-09-308205 (Feb. 2011).
280. Speedy, H. E., Di Bernardo, M. C., *et al.* A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. *Nat Genet* **46,** 56–60. doi:10.1038/ng.2843 (Jan. 2014).
281. Karczewski, K. J., Francioli, L. C., *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581,** 434–443. doi:10.1038/s41586-020-2308-7 (May 2020).
282. Strati, P. & Shanafelt, T. D. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. *Blood* **126,** 454–62. doi:10.1182/blood-2015-02-585059 (July 2015).
283. Stamatopoulos, K., Belessi, C., *et al.* Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. *Blood* **109,** 259–70. doi:10.1182/blood-2006-03-012948 (Jan. 2007).
284. Binder, M., Müller, F., *et al.* CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. eng. *Blood* **121,** 239–241. doi:10.1182/blood-2012-09-454439 (Jan. 2013).
285. Lanasa, M. C., Allgood, S. D., *et al.* Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. *Leukemia* **24,** 133–40. doi:10.1038/leu.2009.192 (Jan. 2010).
286. Vardi, A., Dagklis, A., *et al.* Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. *Blood* **121,** 4521–8. doi:10.1182/blood-2012-12-471698 (May 2013).
287. Kolijn, P. M., Hosnijeh, F. S., *et al.* High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis.

Blood **139,** 1557–1563. doi:10.1182/blood.2021012890 (Mar. 2022).

288. Fazi, C., Scarfo, L., ***et al.*** General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. ***Blood*** **118,** 6618–25. doi:10.1182/blood-2011-05-357251 (Dec. 2011).
289. Criado, I., Rodriguez-Caballero, A., ***et al.*** Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. ***Haematologica*** **103,** 1198–1208. doi:10.3324/haematol.2017.183954 (July 2018).
290. Garcia, M., Juhos, S., ***et al.*** Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. ***F1000Res*** **9,** 63. doi:10.12688/f1000research.16665.2 (Sept. 2020).
291. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. ***Bioinformatics*** **25,** 1754–1760. doi:10.1093/bioinformatics/btp324 (July 2009).
292. McKenna, A., Hanna, M., ***et al.*** The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. en. ***Genome Research*** **20,** 1297–1303. doi:10.1101/gr.107524.110 (Sept. 2010).
293. Kim, S., Scheffler, K., ***et al.*** Strelka2: fast and accurate calling of germline and somatic variants. en. ***Nat Methods*** **15.** Publisher: Nature Publishing Group, 591–594. doi:10.1038/s41592-018-0051-x (Aug. 2018).
294. McLaren, W., Pritchard, B., ***et al.*** Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. ***Bioinformatics*** **26,** 2069–2070. doi:10.1093/bioinformatics/btq330 (Aug. 2010).
295. Morande, P. E., Yan, X. J., ***et al.*** AID overexpression leads to aggressive murine CLL and non-Ig mutations that mirror human neoplasms. ***Blood.*** doi:10.1182/blood.2020008654 (2021).
296. Davi, F. Prehistory of chronic lymphocytic leukemia: clues from the B-cell receptor. en. ***Haematologica*** **109.** Number: 3, 709–711. doi:10.3324/haematol.2023.283799 (2024).
297. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering Signatures of Mutational Processes Operative in Human Cancer. ***Cell Reports*** **3,** 246–259. doi:10.1016/j.celrep.2012.12.008 (Jan. 2013).
298. Okosun, J., Bödör, C., ***et al.*** Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. ***Nature Genetics*** **46,** 176–181. doi:10.1038/ng.2856 (Dec. 2013).
299. Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: An R-based toolkit for single-cell immune receptor analysis. ***F1000Research*** **9,** 47. doi:10.12688/f1000research.22139.2 (June 2020).
300. Hiltemann, S., Jenster, G., Trapman, J., van der Spek, P. & Stubbs, A. Discriminating somatic and germline mutations in tumor DNA samples without matching normals. eng. ***Genome Research*** **25,** 1382–1390. doi:10.1101/gr.183053.114 (Sept. 2015).